IRadimed Corp.

How big is IRadimed Corp.?

As of Jun 18, IRadimed Corp. has a market capitalization of 737.22 million and reported net sales of 75.16 million with a net profit of 19.79 million over the last four quarters.

Market Cap: As of Jun 18, IRadimed Corp. has a market capitalization of 737.22 million, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, IRadimed Corp. reported net sales of 75.16 million and a net profit of 19.79 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 86.82 million, while total assets were reported at 98.33 million.

What does IRadimed Corp. do?

IRadimed Corp. develops and markets MRI-compatible products and non-magnetic intravenous infusion pump systems, classified as a Micro Cap company with a market cap of $737.22 million. As of March 2025, it reported net sales of $20 million and a net profit of $5 million.

Overview: <BR>IRadimed Corp. develops, manufactures, markets, and distributes MRI compatible products and non-magnetic intravenous infusion pump systems, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 20 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 5 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 737.22 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 39.00 <BR>Dividend Yield: 0.82% <BR>Debt Equity: -0.56 <BR>Return on Equity: 21.97% <BR>Price to Book: 8.19<BR><BR>Contact Details: <BR>Address: 1025 Willa Springs Dr, WINTER SPRINGS FL: 32708-5235 <BR>Tel: 1 407 6778022 <BR>Website: http://www.iradimed.com/en-us/

Should I buy, sell or hold IRadimed Corp.?

Who are in the management team of IRadimed Corp.?

As of March 2022, the management team of IRadimed Corp. includes Mr. Roger Susi as Chairman, President, CEO, Founder, and CTO, along with independent directors Mr. Monty Allen, Mr. James Hawkins, and Mr. Anthony Vuoto.

As of March 2022, the management team of IRadimed Corp. includes Mr. Roger Susi, who serves as the Chairman of the Board, President, Chief Executive Officer, Founder, and Chief Technology Officer. Additionally, the board features independent directors: Mr. Monty Allen, Mr. James Hawkins, and Mr. Anthony Vuoto.

Is IRadimed Corp. technically bullish or bearish?

As of July 30, 2025, IRadimed Corp. shows a bullish technical trend with strong MACD and moving averages, despite mixed signals from the RSI and OBV, and has significantly outperformed the S&P 500 year-to-date and over the past year.

As of 30 July 2025, the technical trend for IRadimed Corp. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are bullish, and the moving averages are also bullish on a daily basis. Additionally, the KST and Dow Theory confirm a bullish stance on both weekly and monthly time frames. However, the monthly RSI is bearish, and the OBV shows a mildly bearish signal on the weekly but mildly bullish on the monthly.<BR><BR>In terms of returns, IRadimed has outperformed the S&P 500 over multiple periods, with a year-to-date return of 31.59% compared to the S&P 500's 12.22%, and a one-year return of 49.38% versus 17.14%. Overall, the current technical stance is bullish, driven primarily by the strong MACD and moving averages, despite some mixed signals from the RSI and OBV.

Is IRadimed Corp. overvalued or undervalued?

As of November 21, 2025, IRadimed Corp. is considered overvalued with a P/E ratio of 39 and a PEG ratio of 3.97, despite outperforming the S&P 500 with a year-to-date return of 64.20%.

As of 21 November 2025, the valuation grade for IRadimed Corp. has moved from attractive to fair, indicating a shift in perceived value. The company appears overvalued, given its P/E ratio of 39, which is significantly higher than the industry average, and a PEG ratio of 3.97, suggesting that growth expectations may not justify the current price. Additionally, the Price to Book Value stands at 8.54, further supporting the notion of overvaluation.<BR><BR>In comparison to peers, IRadimed Corp. has a higher P/E ratio than Artivion, Inc. and BioLife Solutions, Inc., which have negative earnings, making direct comparisons challenging. However, Artivion's EV to EBITDA of 44.79 indicates a higher valuation relative to earnings than IRadimed's 30.68. Notably, IRadimed Corp. has outperformed the S&P 500 across multiple time frames, with a year-to-date return of 64.20% compared to the S&P 500's 12.26%, reinforcing the company's strong market performance despite its overvaluation.